Corporate Support
Sitemap
Singapore

ShareInvestor.com

Mobile Edition
Mode - Streaming
Switch to Static Mode?

Price Highlight

Index Highlight

Chart
STI
2,652.7
-16.8 (-0.63%)

 

  • STI Straits Times Index
    2,652.7
    -16.8 (-0.63%)
     
  • KLCI FTSE Bursa Malaysia KLCI
    1,591.8
    8.6 (0.54%)
    Index delayed 15 minutes
  • HSI Hang Seng Index
    25,727.4
    -482.8 (-1.84%)
    Index delayed 15 minutes
  • SSE SSE Composite Index
    3,383.3
    -67.3 (-1.95%)
    Index delayed 15 minutes
  • N225 Nikkei 225
    22,290.8
    -238.5 (-1.06%)
    Index delayed 20 minutes
  • JCI Jakarta Composite Index
    5,031.3
    -21.5 (-0.43%)
    Index delayed 10 minutes

SGX Market

Bursa Market

HKEx Market

SET Market

IDX Market

ASX Market

NYSE Market

NASDAQ Market

NYSE American Market

  • Volume: 2,451.9M
  • Value: 1,077.1M
  • Rise: 168
  • Fall: 215
  • Unch: 425

Intraday Market Ticker Help

Intraday Market Ticker
Time Name Type Price Vol
  • Top Active

  • Top Gainer

  • Top Loser

Top Counters
Name Last Change
QT Vascular0.009+0.004
AsiaMedic0.031+0.011
Adventus0.025+0.005
Singapore-eDev0.130-0.003
Anchor Resources0.007+0.001
Medtecs Intl0.870+0.050
Clearbridge0.185+0.013
Biolidics0.410+0.100
3Cnergy0.019+0.002
Thomson Medical0.060+0.001

World Indices

World Indices
Name Last Change
Nasdaq 9,757.2 -259.8
HSI 24,265.5 -284.5
HSCEI 9,743.2 -110.0
Jakarta 4,863.1 -41.0
Nikkei 225 22,047.8 -464.2
SSE Comp 2,960.5 -10.1
Shanghai A 3,103.1 -10.6
Shanghai B 211.8 -1.7
KOSPI 2,097.3 -37.3

Asian Indices delayed. US Indices updated twice daily at 7:30am and 7:30pm.

Fundamental - Factsheet

Help
  • Factsheet

  • Print

IX Biopharma IX BIOPHARMA LTD.
Quotes 10 Minutes Delayed. Updated at 09 Jul 2020 17:14
Last (SGD): 0.255 Change: +0.005 High: 0.275 Remarks: -
Change (%): +2.00 Low: 0.250
Open 0.250 Yesterday's Close 0.250
Buy Price 0.255 Sell Price 0.260
Buy Volume ('000) 1,088.2 Sell Volume ('000) 264.4
Cumulative Volume ('000) 26,917.2 Cumulative Value 7,049,268
Click to show Stock Prices chart

Key Statistics

EPS (SGD) a -0.00461 Trailing EPS (SGD) e -0.00295 NAV (SGD) b 0.0233
PE a - Trailing PE f - Price / NAV b 10.9442
Dividend (SGD) d - Cash In Hand (SGD) g 0.0148 Issued & Paid-up Shares c 648,894,000
Dividend Yield (%) d - Price / Cash In Hand g 17.230 Treasury Shares h -
Beta - 75 Daysi 0.418 R-Squared - 75 Days(%)i 0.46 Market Cap (M) 165.468
Beta - 500 Daysi 0.536 R-Squared - 500 Days (%)i 1.60 Enterprise Value (M) 158.809
Piotroski F Score 1 Exchange Code 42C Par Value ( SGD ) n.a.
52 Weeks Volatility (%) 65.8598 6-Month VWAP 0.270 Free Float (%) 46.0
Under CPF Investment Scheme (CPFIS) No
Sector & Industry Prof, Scientific & Technical Activities - Pharmaceuticals: Major
Category Classification Medical & Biotechnology
Notes:
  1. Based on latest Full Year results announcement, adjusted for the current number of shares.
  2. Based on latest results announcement (Full Year, Half Year or Interim), adjusted for carrying value of "Other Share Capital", illustrative financial effects of corporate actions (if applicable) and the current number of shares.
  3. Rounded to the nearest thousand. Updated on 12 Feb 2020.Please click here for more information.
  4. Dividend is based on latest Full Year results announcement, adjusted for current number of shares and excludes special dividend.
  5. Summation of the earnings from the latest 4 Quarter (or 2 Half Year) results announcement, adjusted for the current number of shares.
  6. Based on Trailing EPS.
  7. Based on reported cash and cash equivalents at end and extracted from the latest results announcement (Full Year, Half Year or Interim), adjusted for the current number of shares.
  8. Rounded to the nearest thousand.
  9. Beta and R-Squared are calculated in relation to the market index (STI or KLCI) using the historical daily closing values of the stock and index as data points.

Peer Comparison

Type Name Market Market Cap (M)a PE b Trailing PE c Price / NAV d Dividend Yield (%)d
Reference IX Biopharma SGX 165.468 - - 10.9442 -
Industry Medical & Biotechnology SGX 937.449 20.731 22.772 1.3171 2.046
Pharmaceuticals: Major SGX 91.081 2151.512 143.812 3.7303 1.100
Local Peer Hyphens Pharma SGX 100.644 15.409 13.930 2.1810 2.985
Local Peer Pharmesis Intl SGX 7.130 - - 0.5944 -
Global Peer JOHNSON & JOHNSON NYSE 375,086.578 24.809 21.851 6.1195 2.632
Global Peer NOVARTIS AG ADR-EACH REPR 1 CHF0.5(REGD) NYSE 214,658.891 30.456 21.508 - 2.117
Global Peer MERCK & CO INC NYSE 193,674.193 19.676 19.087 7.3907 2.963
Global Peer PFIZER INC NYSE 187,919.899 11.549 11.901 2.8907 4.300
Global Peer ABBVIE INC NYSE 170,647.382 21.761 20.337 -23.0137 3.805
Global Peer ELI LILLY AND COMPANY NYSE 156,341.728 33.710 28.255 50.7802 1.580
Global Peer ASTRAZENECA SPON ADR EACH REP 0.50 ORD SHS NYSE 141,095.270 105.253 189.712 - 2.548
Global Peer BRISTOL-MYERS SQUIBB CO NYSE 129,946.287 37.786 136.212 2.6036 2.880
Global Peer SANOFI SPON ADR ECH REP 0.5 ORD SHS NASDAQ 126,322.466 38.825 38.770 1.9095 2.330
Global Peer NOVO NORDISK A/S ADR-EACH CNV INTO 1 CLASS B DKK1 NYSE 118,613.926 20.314 19.741 14.8289 1.738
Other Global Peers GLAXOSMITHKLINE ADR EACH CNV INTO 2 ORD GBP0.25 (NYSE), TAKEDA PHARMACEUTICAL CO LTD SPON ADS EACH REP 0.5 ORD SHS (NYSE), WUXI APPTEC (HKEx), ROYALTY PHARMA PLC (NASDAQ), HANSOH PHARMA (HKEx), INNOVENT BIO (HKEx), SINOPHARM (HKEx), REPLIGEN CORP (NASDAQ), CANSINOBIO-B (HKEx), SH PHARMA (HKEx), REATA PHARMACEUTICALS INC (NASDAQ), LEGEND BIOTECH CORP SPON ADS EACH REP 2 ORD SHS (NASDAQ), BAIYUNSHAN PH (HKEx), GRIFOLS SA SPON ADR EA REPR 1 ORD EUR0.10 (NASDAQ), BIOHAVEN PHARMACEUTICAL HLDG CO LTD (NYSE), NEKTAR THERAPEUTICS (NASDAQ), CHINARES PHARMA (HKEx), HUTCHISON CHINA MEDITECH SPON ADS EACH REPR 5 ORD SHS (NASDAQ), HENLIUS-B (HKEx), AKESO-B (HKEx), HEPALINK (HKEx), ALLAKOS INC (NASDAQ), CMS (HKEx), ADC THERAPEUTICS SA (NYSE), OCUMENSION-B (HKEx), TRAD CHI MED (HKEx), OPKO HEALTH INC (NASDAQ), CHINAGRANDPHARM (HKEx), KARUNA THERAPEUTICS INC (NASDAQ), TURNING POINT THERAPEUTICS INC (NASDAQ), INNOCARE-B (HKEx), HYGEIA HEALTH (HKEx), APELLIS PHARMACEUTICALS INC (NASDAQ), IGM BIOSCIENCES INC (NASDAQ), PRINCIPIA BIOPHARMA INC (NASDAQ), SSY GROUP (HKEx), FORMA THERAPEUTICS HLDGS INC (NASDAQ), I MAB SPON ADS EACH REP 2.3 ORD SHS (NASDAQ), UNITED LAB (HKEx), SPRINGWORKS THERAPEUTICS INC (NASDAQ), Y-MABS THERAPEUTICS INC (NASDAQ), ZYMEWORKS INC (NYSE), CSTONE PHARMA-B (HKEx), ZEALAND PHARMA AS SPON ADR EACH REP 1 ORD SHS (NASDAQ), CONSTELLATION PHARMACEUTICALS INC (NASDAQ), AMNEAL PHARMACEUTICALS INC (NYSE), JUNSHI BIO-B (HKEx), KINIKSA PHARMACEUTICALS LTD (NASDAQ), AKCEA THERAPEUTICS INC (NASDAQ), TRICIDA INC (NASDAQ), AKERO THERAPEUTICS INC (NASDAQ), CKLIFE SCIENCES (HKEx), ODONATE THERAPEUTICS INC (NASDAQ), TONGRENTANGCM (HKEx), ARCUTIS BIOTHERAPEUTICS INC (NASDAQ), ATHENEX INC (NASDAQ), PHIBRO ANIMAL HEALTH CORP (NASDAQ), IMMUNOTECH-B (HKEx), GOSSAMER BIO INC (NASDAQ), PETIQ INC (NASDAQ), ARCTURUS THERAPEUTICS HOLDINGS INC (NASDAQ), REPARE THERAPEUTICS INC (NASDAQ), GENERATION BIO CO (NASDAQ), HUA MEDICINE-B (HKEx), PHATHOM PHARMACEUTICALS INC (NASDAQ), KRYSTAL BIOTECH INC (NASDAQ), QUANTERIX CORPORATION (NASDAQ), G1 THERAPEUTICS IN (NASDAQ), ORIC PHARMACEUTICALS INC (NASDAQ), PROVENTION BIO INC (NASDAQ), FUSION PHARMACEUTICALS INC (NASDAQ), APPLIED THERAPEUTICS INC (NASDAQ), KEROS THERAPEUTICS INC (NASDAQ), NAVIDEA BIOPHARMACEUTICALS INC (NYSE American), RELMADA THERAPEUTICS INC (NASDAQ), OYSTER POINT PHARMA INC (NASDAQ), APREA THERAPEUTICS INC (NASDAQ), CALLIDITAS THERAPEUTICS AB SPON ADS EACH REP 2 ORD SHS (NASDAQ), KALA PHARMACEUTICALS INC (NASDAQ), IGBB (Bursa), SHINEWAY PHARM (HKEx), FULCRUM THERAPEUTICS INC (NASDAQ), 89BIO INC (NASDAQ), OSMOTICA PHARMACEUTICALS PLC (NASDAQ), ORCHARD THERAPEUTICS PLC SPON ADS EACH REPR 1 ORD SHS (NASDAQ), AC IMMUNE SA (NASDAQ), CRINETICS PHARMACEUTICALS INC (NASDAQ), MIRUM PHARMACEUTICALS INC (NASDAQ), Kimia Farma Tbk. (IDX), OCULAR THERAPEUTIX INC (NASDAQ), BIOSPECIFICS TECHNOLOGIES CORP (NASDAQ), SIGA TECHNOLOGIES INC (NASDAQ), BEYONDSPRING INC (NASDAQ), SATSUMA PHARMACEUTICALS INC (NASDAQ), IMARA INC (NASDAQ), DURECT CORP (NASDAQ), OVID THERAPEUTICS INC (NASDAQ), AEGLEA BIOTHERAPEUTICS INC (NASDAQ), TCR2 THERAPEUTICS INC (NASDAQ), IDEAYA BIOSCIENCES INC (NASDAQ), TOT BIOPHARM-B (HKEx), AMRYT PHARMA PLC (NEW) SPON ADS EACH REP 5 ORD SHS (NASDAQ), FUSEN PHARM (HKEx), SUTRO BIOPHARMA INC (NASDAQ), STARPHARMA HOLDINGS LIMITED (ASX), GRITSTONE ONCOLOGY INC (NASDAQ), LIQUIDIA TECHNOLOGIES INC (NASDAQ), UROVANT SCIENCES LTD (NASDAQ), MENLO THERAPEUTICS INC (NASDAQ), AFT PHARMACEUTICALS LTD (ASX), BIONDVAX PHARMACEUTICALS SPON ADS REP 40 ORD SHS (NASDAQ), SPERO THERAPEUTICS INC (NASDAQ), PYC THERAPEUTICS LIMITED (ASX), HOOKIPA PHARMA INC (NASDAQ), BSTEAD (Bursa), AMAG PHARMACEUTICS INC (NASDAQ), VERRICA PHARMACEUTICALS INC (NASDAQ), POLYPID LTD (NASDAQ), KALEIDO BIOSCIENCES INC (NASDAQ), REDHILL BIOPHARMA LTD SPON ADS EA REPR 10 ORD ILS0.00 (NASDAQ), LANNETT CO INC (NYSE), KALVISTA PHARMACEUTICALS INC (NASDAQ), GAMIDA CELL LTD (NASDAQ), VERU INC (NASDAQ), SCPHARMACEUTICALS INC (NASDAQ), EVELO BIOSCIENCES INC (NASDAQ), NEUBASE THERAPEUTICS INC (NASDAQ), SOL GEL TECHNOLOGIES LTD (NASDAQ), CH BIOTECH SER (HKEx), IMMUNIC INC (NASDAQ), DAWNRAYS PHARMA (HKEx), LOGICBIO THERAPEUTICS INC (NASDAQ), GALERA THERAPEUTICS INC (NASDAQ), THERATECHNOLOGIES INC (NASDAQ), MUSTANG BIO INC (NASDAQ), AVENUE THERAPEUTICS INC (NASDAQ), LYRA THERAPEUTICS INC (NASDAQ), PROTARA THERAPEUTICS INC (NASDAQ), TYME TECHNOLOGIES INC (NASDAQ), CYCLERION THERAPEUTICS INC (NASDAQ), AQUESTIVE THERAPEUTICS INC (NASDAQ), PHARMA (Bursa), OBSEVA SA (NASDAQ), PHASEBIO PHARMACEUTICALS INC (NASDAQ), ESSA PHARMA INC (NASDAQ), HARROW HEALTH INC (NASDAQ), AYALA PHARMACEUTICALS INC (NASDAQ), ZHONGZHIPHARM (HKEx), CORVUS PHARMACEUTICALS INC (NASDAQ), BIOMX INC (NYSE American), TFF PHARMACEUTICALS INC (NASDAQ), GENPREX INC (NASDAQ), XERIS PHARMACEUTICALS INC (NASDAQ), EVOLUS INC (NASDAQ), ETON PHARMACEUTICALS INC (NASDAQ), APTORUM GROUP LIMITED (NASDAQ), RECCE PHARMACEUTICALS LTD (ASX), TREVI THERAPEUTICS INC (NASDAQ), CHECKPOINT THERAPEUTICS INC (NASDAQ), KITOV PHARMA LTD SPON ADS EACH REP 1 ORD SHS (NASDAQ), MEDIWOUND LTD (NASDAQ), Merck Tbk. (IDX), KOTRA (Bursa), EYEPOINT PHARMACEUTICALS INC (NASDAQ), PAK FAH YEOW (HKEx), NEW RAY MEDIC (HKEx), MILESTONE PHARMACEUTICALS INC (NASDAQ), THE FS ALSEC ALPHASECTOR (NASDAQ), CHARMACY PHAR (HKEx), NC HEALTHCARE (HKEx), LANTERN PHARMA INC (NASDAQ), CLEARSIDE BIOMEDICAL INC (NASDAQ), ONCOSIL MEDICAL LIMITED (ASX), IP (SET), Phapros Tbk. (IDX), PALLA PHARMA LTD (ASX), RACE ONCOLOGY LTD (ASX), BAUDAX BIO INC (NASDAQ), CITIUS PHARMACEUTICALS INC (NASDAQ), ARIDIS PHARMACEUTICAL INC (NASDAQ), AKARI THERAPEUTICS PLC SPON ADR EACH REPR 100 ORD (NASDAQ), ADDEX THERAPEUTICS LIMITED SPON ADS EACH REP 6 ORD SHS (NASDAQ), NOVA (Bursa), EYENOVIA INC (NASDAQ), MOLECULIN BIOTECH INC (NASDAQ), AERPIO PHARMACEUTICALS INC (NASDAQ), NEP INTERLONG (HKEx), ALLENA PHARMACEUTICALS INC (NASDAQ), ADAMIS PHARMACEUTICALS CORPORATION (NASDAQ), EDESA BIOTECH INC (NASDAQ), WAI YUEN TONG (HKEx), INVION LTD (ASX), MANNATECH INC (NASDAQ), ANNOVIS BIO INC (NYSE American), AILERON THERAPEUTICS INC (NASDAQ), TBG DIAGNOSTICS LTD (ASX), NOVAN INC (NASDAQ), ONCTERNAL THERAPEUTICS INC (NASDAQ), NOXOPHARM LTD (ASX), PURAPHARM (HKEx), HISTOGEN INC (NASDAQ), ACER THERAPEUTICS INC (NASDAQ), SANAI HEALTH GP (HKEx), EXTRAWELL PHAR (HKEx), HOTH THERAPEUTICS INC (NASDAQ), AGEX THERAPEUTICS INC (NYSE American), JCT (SET), MILLENDO THERAPEUTICS INC (NASDAQ), ENTERA BIO LTD (NASDAQ), PDS BIOTECHNOLOGY CORPORATION (NASDAQ), IMMURON LIMITED (ASX), CNS PHARMACEUTICALS INC (NASDAQ), BIOHLDG (Bursa), MEDLAB CLINICAL LIMITED (ASX), IMMURON LIMITED SPON ADR EACH REPR 40 ORD SHS (NASDAQ), TITAN PHARMACEUTICAL INC (NASDAQ), TIMBER PHARMACEUTICALS INC (NYSE American), DARE BIOSCIENCE INC (NASDAQ), SPRING BANK PHARMACEUTICALS INC (NASDAQ), BRICKELL BIOTECH INC (NASDAQ), PHARMAXIS (ASX), SINOLIFE UTD (HKEx), ADIAL PHARMACEUTICALS INC (NASDAQ), EXOPHARM LTD (ASX), PROPHASE LABS INC (NASDAQ), ACRUX (ASX), PASHUN INT'L (HKEx), CHINA SXT PHARMACEUTICALS INC (NASDAQ), TALI DIGITAL LIMITED (ASX), SUNZEN (Bursa), CELLMID LIMITED (ASX), TELIGENT INC NEW (NASDAQ), CRESO PHARMA LTD (ASX), NOVUS THERAPEUTICS INC (NASDAQ), Merck Sharp Dohme Pharma Tbk. (IDX), SUDA PHARMACEUTICALS LTD (ASX), FARMAFORCE LTD (ASX), FIJI KAVA LTD (ASX)
Notes:
  1. For companies, Market Cap is based on the trading currency of the company. Industry/Index Market Cap is the average market cap for that industry/index.
  2. Industry/Index PE is calculated using (Total Market Cap/Total Earnings) of all companies in the industry/index.
  3. Industry/Index Price/NAV is calculated using (Total Market Cap/Total Shareholders' Equity) of all companies in the industry/index.
  4. Industry/Index Dividend Yield is calculated using (Total Gross Dividend/Total Market Cap) of all companies in the industry/index.
  5. For Industry/Index calculation, data for foreign currency denominated companies will be converted to the main market currency using the latest exchange rate.
  6. Industry/Index/Peers data is updated daily.
  7. Peers are sorted by market capitalisation and only details for the top 10 will be shown.

Total Shareholder Return

PeriodDividend ReceivedCapital AppreciationTotal Shareholder Return
Short Term Return 5 Days -+0.010
+4.08 %
10 Days -+0.010
+4.08 %
20 Days -+0.005
+2.00 %
Medium Term Return 3 Months -+0.081
+46.55 %
6 Months -+0.040
+18.60 %
1 Year --0.010
-3.77 %
Long Term Return 2 Years -+0.082
+47.40 %
3 Years ---
Annualised Return Annualised ---
Notes:
  1. Total Shareholder Return (TSR) combines share price appreciation and dividends paid to show the total return to the shareholder expressed as a percentage.
  2. Script dividends are ignored in this calculation.

Price Movements

1 Year Range 0.130 - 0.335 Change From 1 Year Low +0.125 % Change From 1 Year Low (%) +96.15
Change From 1 Year High -0.080 % Change From 1 Year High (%) -23.88
2 Years Range 0.130 - 0.335 Change From 2 Years Low +0.125 % Change From 2 Years Low (%) +96.15
Change From 2 Years High -0.080 % Change From 2 Years High (%) -23.88
5 Years Range 0.130 - 0.631 Change From 5 Years Low +0.125 % Change From 5 Years Low (%) +96.15
Change From 5 Years High -0.376 % Change From 5 Years High (%) -59.61
Notes:
  1. Price movements are based on adjusted historical data.

Company Background

The Company was incorporated in Singapore on 8 May 2004 as a private company limited under the name of Ixblue International Pte. Ltd. On 22 January 2008, the name of its Company was changed to iX Biopharma Pte Ltd. The Company was converted into a public limited company and the name of its Company was changed to iX Biopharma Ltd on 31 January 2013.iX Biopharma Ltd. focuses on the development and commercialisation of innovative therapies for pain management and male erectile dysfunction. The Company leverages its patented sublingual drug delivery technology, WaferiXTM, to develop proprietary products that incorporate FDA-approved pharmacologically active compounds. The Group currently have three drugs under development - Wafermine™, Wafernyl™ and PheoniX™.The Group operates an integrated business model encompassing drug development, manufacturing and supply. Its manufacturing facility in Australia is TGA-approved and GMP-compliant, and supplies drugs to hospitals under Schedule 5A of the TGR.

IPO Performance

Listing Date 22 Jul 2015 Full Subscription Rate (x) 1.36
No of Placement Shares (M) 64.50 No of Public Offer Shares (M) 1.00 Public Offer Subscription Rate (x) 24.65
IPO Price (SGD) a 0.454 First Day Close (SGD) a 0.552 First Week Close (SGD) a 0.414
Current vs IPO Price (%) -43.83 First Day Gain (%) +21.59 First Week Gain (%) -8.81
Notes:
  1. Adjusted for the following: Rights Issue 1 for 25 @ $0.21 on 22/06/2016

Reports Download

Report Type Financial Year Ended Download
Annual Report
Annual Report 2019 Jun 2019 Part 1(4.31 MB)
Annual Report 2018 Jun 2018 Part 1(6.28 MB)
Annual Report 2017 Jun 2017 Part 1(1.40 MB)
Annual Report 2016 Jun 2016 Part 1(4.32 MB)
Part 2(0.12 MB)
Annual Report 2015 Jun 2015 Part 1(0.59 MB)
IPO Prospectus
IPO Prospectus 2015 Jul 2015 Part 1(3.65 MB)

Historical Price Data

Date Open High Low Close Volume VWAP
09 Jul 2020 0.250 0.275 0.250 0.255 26,917,200 0.2619
08 Jul 2020 0.245 0.260 0.240 0.250 9,549,100 0.2523
07 Jul 2020 0.250 0.250 0.240 0.245 2,139,900 0.2447
06 Jul 2020 0.250 0.250 0.245 0.250 2,479,400 0.2461
03 Jul 2020 0.250 0.250 0.245 0.245 1,170,600 0.2456
02 Jul 2020 0.250 0.250 0.245 0.245 1,807,400 0.2483
01 Jul 2020 0.250 0.260 0.245 0.250 2,705,600 0.2502
30 Jun 2020 0.270 0.275 0.250 0.250 10,609,800 0.2617
29 Jun 2020 0.240 0.250 0.240 0.245 1,810,400 0.2446
26 Jun 2020 0.255 0.255 0.245 0.245 561,700 0.2476
25 Jun 2020 0.250 0.255 0.245 0.245 1,309,500 0.2478
24 Jun 2020 0.265 0.265 0.250 0.255 1,729,200 0.2556
23 Jun 2020 0.245 0.265 0.240 0.260 7,317,600 0.2573
22 Jun 2020 0.255 0.255 0.245 0.245 1,165,500 0.2476
19 Jun 2020 0.250 0.260 0.245 0.250 2,458,700 0.2524
18 Jun 2020 0.245 0.250 0.245 0.245 1,698,400 0.2462
17 Jun 2020 0.250 0.250 0.240 0.240 1,110,300 0.2444
16 Jun 2020 0.245 0.250 0.240 0.250 1,531,500 0.2444
15 Jun 2020 0.250 0.255 0.240 0.240 1,693,400 0.2452
12 Jun 2020 0.240 0.250 0.235 0.250 2,442,400 0.2443
11 Jun 2020 0.260 0.265 0.245 0.250 2,233,900 0.2515
10 Jun 2020 0.260 0.270 0.260 0.260 2,525,600 0.2621
Summary
Current 2 Weeks
(26 Jun 2020 to 09 Jul 2020)
0.255 0.275 0.240 0.255 59,751,100 -
Previous 2 Weeks
(12 Jun 2020 to 25 Jun 2020)
0.240 0.275 0.235 0.245 22,456,500 -
4 Weeks from
(14 May 2020 to 11 Jun 2020)
0.265 0.275 0.240 0.250 116,181,100 -
View All Historical Data

More Information Available

More information is available to our subscribers, including:

  • Market Moving News from Dow Jones Newswires
  • Consensus Estimates
  • Dividend/Distribution History
  • Financial Summary with Financial Period Comparison
  • Comprehensive Financial Ratios(ROA, ROE, Price/Revenue, Net Earnings Margin, Current Ratio, Debt to Equity Ratio etc)
  • Events Calendar for Results Announcements, Ex-Dates etc
  • Insider Buying and Selling Report

If you are an existing subscriber, please login. If not, read up on what you are missing out in our Help Centre and join us as a subscriber.

Disclaimer:

While reasonable efforts have been taken to ensure that the calculations performed by the features of this site are reliable, the features are provided on the basis that:-

  1. no liability is accepted for any errors or inaccuracies resulting from your use of these features;
  2. many of the data inputs (including share prices) are obtained from third party sources for which we assume no responsibility.
We use Cookies. By continuing to use this webite, you will be agreeing to our Privacy Policy, Terms and Conditions and Cookie Policy.